Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 36 references it cites were found in a registry or an index.

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Open access

Abstract

BACKGROUND Immune checkpoint inhibitors have not shown clinical benefit to patients with metastatic colorectal cancer who had proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumours in previous studies. Both an active combination chemotherapy (FOLFOXIRI; fluorouracil, leucovorin, oxaliplatin, and irinotecan) and bevacizumab seem able to increase the immunogenicity of pMMR or MSS tumours. We aimed to provide preliminary evidence of benefit from the addition of the anti-PD-L1 agent atezolizumab to first-line FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer. METHODS AtezoTRIBE was a multicentre, open-label, randomised, controlled, phase 2 study of patients (aged 18-70 years with an Eastern Cooperative Oncology Group [ECOG] performance status of 0-2 and aged 71-75 years with an ECOG performance status of 0) with histologically confirmed, unresectable, previously untreated metastatic colorectal cancer and adequate organ function, who were recruited from 22 oncology centres in Italy. Patients were stratified according to centre, ECOG performance status, primary tumour site, and previous adjuvant therapy. A randomisation system incorporating a minimisation algorithm randomly assigned (1:2) patients via a masked web-based allocation procedure to two groups: the control group received first-line FOLFOXIRI (intravenous 165 mg/m2 irinotecan, 85 mg/m2 oxaliplatin, 200 mg/m2 leucovorin, and 3200 mg/m2 fluorouracil as a 48 h infusion) plus bevacizum…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(22)00274-1

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Research works printed but not linked: 1

  1. Lee, 2018, Proc Am Soc Clin Oncol, 36

Cited by

See all 280

Metadata

Authors
Antoniotti, C., Rossini, D., Pietrantonio, F., Catteau, A., Salvatore, L., Lonardi, S., Boquet, I., Tamberi, S., Marmorino, F., Moretto, R., Ambrosini, M., Tamburini, E., Tortora, G., Passardi, A., Bergamo, F., Kassambara, A., Sbarrato, T., Morano, F., Ritorto, G., Borelli, B., Boccaccino, A., Conca, V., Giordano, M., Ugolini, C., Fieschi, J., Papadopulos, A., Massoué, C., Aprile, G., Antonuzzo, L., Gelsomino, F., Martinelli, E., Pella, N., Masi, G., Fontanini, G., Boni, L., Galon, J., & Cremolini, C.
Affiliations
  • University of Pisa (IT)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Università Cattolica del Sacro Cuore (IT)
  • Istituto Oncologico Veneto (IT)
  • Ospedale "Santa Maria delle Croci" di Ravenna (IT)
  • Pia Fondazione di Culto e Religione Azienda Ospedaliera "Card. G. Panico" (IT)
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
  • Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
  • Ospedale San Bortolo (IT)
  • Azienda Ospedaliero-Universitaria Careggi (IT)
  • Azienda Ospedaliero-Universitaria di Modena (IT)
  • University of Campania "Luigi Vanvitelli" (IT)
  • Azienda sanitaria universitaria Friuli Centrale (IT)
  • Ospedale Policlinico San Martino (IT)
  • Inserm (FR)
Corresponding author
Cremolini, Chiara
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2022-07
Volume
23
Issue
7
Pages
876-887
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4281627748
Cited by
280
References
36
Citations by year
2026: 50 · 2025: 69 · 2024: 89 · 2023: 58 · 2022: 14
FWCI
24.05
Type
journal article
Language
en
Open access
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by-nc-nd)
  • Florence Research (University of Florence) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
metastatic colorectal cancer, FOLFOXIRI, bevacizumab, atezolizumab, PD-L1 blockade, immune checkpoint inhibitors, first-line therapy, proficient mismatch repair, immunogenicity, progression-free survival, maintenance therapy, irinotecan, oxaliplatin
MeSH terms
Bevacizumab, Irinotecan, Oxaliplatin, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Colonic Neoplasms, Fluorouracil, Humans, Organoplatinum Compounds, Rectal Neoplasms, Colorectal Neoplasms, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(22)00274-1
The paper
Antoniotti, C., Rossini, D., Pietrantonio, F., Catteau, A., Salvatore, L., Lonardi, S., Boquet, I., Tamberi, S., Marmorino, F., Moretto, R., Ambrosini, M., Tamburini, E., Tortora, G., Passardi, A., Bergamo, F., Kassambara, A., Sbarrato, T., Morano, F., Ritorto, G., . . . Cremolini, C. (2022). Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(22)00274-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.